Komori
Immuno-Biological Laboratories (4570) · InitiativeAchieved

Covering the Deficit through Reductions in Capital and Capital Reserve and Implementing a Flexible Capital Policy

First written in FY2024-Q1. 1 of 2 entries say "Achieved", first in FY2024-Q2. Latest entry: FY2024-Q2.

2entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024-Q12023: 22023
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2AchievedAnnual report

    「At the 41st Annual General Meeting of Shareholders held on 29 June 2023, the Company resolved to reduce the amounts of capital and capital reserves and dispose of surplus. With 29 August 2023 as the effective date, it reduced capital by ¥2,979.041 million and capital reserves by ¥1,021.014 million, respectively, and transferred the same amounts to other capital surplus. In addition, pursuant to Article 452 of the Companies Act, the Company offset the deficit by transferring ¥4,000.056 million in other capital surplus to retained earnings brought forward. As a result, as of the end of the current second-quarter consolidated accounting period, capital was ¥50 million, capital surplus was ¥1,040.407 million, and retained earnings were ¥17.061 million.」

    The reduction in capital and capital reserves and the deficit offset became effective on 29 August 2023. Capital declined from ¥3,029.041 million to ¥50 million, capital reserves declined from ¥2,061.421 million to ¥1,040.407 million, and retained earnings amounted to ¥17.061 million after ¥4,000.056 million in deficit offsetting.
  2. FY2024-Q1First statedAnnual report

    「The purpose is to offset the deficit in retained earnings brought forward that has currently arisen and strengthen the financial position, while taking advantage of tax benefits such as reduced tax burdens, and to prepare for the implementation of flexible capital policies and shareholder-return measures in the future.」

    Based on a resolution at the General Meeting of Shareholders held on 29 June 2023, the Company described a plan to reduce capital by ¥2,979.041 million and capital reserves by ¥1,021.014 million, and allocate the full ¥4,000.056 million in other capital surplus to offset the deficit in retained earnings brought forward. The effective date was set as 29 August 2023.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.